SAB Biotherapeutics (SABS) director files Form 3 showing no stock

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. director David Zaccardelli filed an initial beneficial ownership report on Form 3, with an event date of 01/05/2026. The filing states that no securities of SAB Biotherapeutics are beneficially owned, and both the non-derivative and derivative tables show no holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ZACCARDELLI DAVID

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/05/2026

3. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Grant Levine, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed this Form 3 for SAB Biotherapeutics (SABS)?

The Form 3 was filed by David Zaccardelli, who is identified as a director of SAB Biotherapeutics, Inc..

What is the relationship of David Zaccardelli to SAB Biotherapeutics (SABS)?

David Zaccardelli is reported as a director of SAB Biotherapeutics, Inc. and is not listed as an officer or 10% owner.

Does David Zaccardelli own any SAB Biotherapeutics (SABS) shares according to this Form 3?

No. The filing’s explanation of responses states that no securities are beneficially owned, and both non-derivative and derivative tables show no holdings.

What is the date of the event requiring this Form 3 filing for SAB Biotherapeutics (SABS)?

The date of the event requiring the statement is listed as 01/05/2026.

Is this Form 3 filed by multiple reporting persons for SAB Biotherapeutics (SABS)?

No. The Form 3 is indicated as filed by one reporting person, not by more than one reporting person.

Does this Form 3 disclose any derivative securities for SAB Biotherapeutics (SABS)?

No. The table for Derivative Securities Beneficially Owned contains no entries, and the explanation states that no securities are beneficially owned.